Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types
Brain · 04.12.2025 · 148 (12) · 4578-4591
DOI: 10.1093/brain/awaf331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 02.12.2025. Verfasst von Charles Willard und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Analysis, Queen Square Analytics Limited, London EC1V 2NX, UK. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Neurofilament Proteins, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck KGaA, Arman Eshaghi, National Institute for Health and Care Research.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a highly heterogeneous disease in its clinical manifestation and progression. Predicting individual disease courses is key for aligning treatments with underlying pathobiology. We developed an unsupervised machine learning model integrating MRI-derived measures with serum neurofilament light chain (sNfL) levels to identify biologically informed MS subtypes and stages. Using a training cohort of patients with relapsing–remitting and secondary progressive MS (n = 189), with validation on a newly diagnosed population (n = 445), we discovered two distinct subtypes defined by the timing of sNfL elevation and MRI abnormalities (early- and late-sNfL types). In comparison to MRI-only models, incorporating sNfL with MRI improved correlations of data-derived stages with the Expanded Disability Status Scale in the training (Spearman’s ρ = 0.420 versus MRI-only ρ = 0.231, P = 0.001) and external test sets (ρ = 0.163 for MRI–sNfL, versus ρ = 0.067 for MRI-only). The early-sNfL subtype showed elevated sNfL, corpus callosum injury and early lesion accrual, reflecting more active inflammation and neurodegeneration, whereas the late-sNfL group showed early volume loss in the cortical and deep grey matter volumes, with later sNfL elevation. Cross-sectional subtyping predicted longitudinal radiological activity: the early-sNfL group showed a 144% increased risk of new lesion formation (hazard ratio = 2.44, 95% confidence interval 1.38–4.30, P < 0.005) compared with the late-sNfL group. Baseline subtyping, over time, predicted treatment effect on new lesion formation on the external test set (faster lesion accrual in early-sNfL compared with late-sNfL, P = 0.01), in addition to treatment effects on brain atrophy (early sNfL average percentage brain volume change: −0.41, late-sNfL = −0.31, P = 0.04). Integration of sNfL provides an improved framework in comparison to MRI-only subtyping of MS to stage disease progression and inform prognosis. Our model predicted treatment responsiveness in early, more active disease states. This approach offers a powerful alternative to conventional clinical phenotypes and supports future efforts to refine prognostication and guide personalized therapy in MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Analysis, Queen Square Analytics Limited, London EC1V 2NX, UK.
- Department of Mathematics and Computer Science, University of Catania, Catania 95124, Italy.
- MIFT Department, University of Messina, Messina 98122, Italy.
- MS Center Amsterdam, Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands.
- Department of Medical Physics and Biomedical Engineering, University College London, London WC1E 6BT, UK.
- Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam 1081 BT, The Netherlands.
ORCID-Profile: Charles Willard
Förderung
- Merck KGaA
- Arman Eshaghi
- National Institute for Health and Care Research
- NIHR
- United Kingdom Department of Health and Social Care
Zitieren
APA
Willard, C., Puglisi, L., Ravi, D., Dmitrieva, M., Mattiesing, R. M., Barkhof, F., Alexander, D. C., Harlow, D. E., Piani-Meier, D., & Eshaghi, A. (2025). Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types. Brain, 148(12), 4578-4591. https://doi.org/10.1093/brain/awaf331
Vancouver
Willard C, Puglisi L, Ravi D, Dmitrieva M, Mattiesing RM, Barkhof F, et al. Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types. Brain. 2025;148(12):4578-4591. doi:10.1093/brain/awaf331
BibTeX
@article{Willard2025,
author = {Willard, Charles and Puglisi, Lemuel and Ravi, Daniele and Dmitrieva, Mariia and Mattiesing, Rozemarijn M and Barkhof, Frederik and Alexander, Daniel C and Harlow, Danielle E and Piani-Meier, Daniela and Eshaghi, Arman},
title = {Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types},
journal = {Brain},
year = {2025},
volume = {148},
number = {12},
pages = {4578--4591},
doi = {10.1093/brain/awaf331}
}
EUVIMED